Precision Quantomics develops next-generation proteomics-based assays and quantitative in vitro platforms that enhance drug candidate selection, reduce reliance on animal models, and forecast drug metabolism, transport, toxicity, and disease risk—aligning with modern regulatory expectations and advancing therapeutic innovation.
Explore Precision Quantomics
Who are PQ's typical clients?
The typical clients of PQ are pharmaceutical and biotech industry, academic laboratories, contract research organizations, biological reagent companies and diagnostic laboratories.
How do our products and services support drug development and precision medicine?
We strive for the development of cost effective, safe and efficacious drugs by delivering innovative tools to our clients that help to cure a wide range of diseases. We also provide tools for precision pharmacotherapy and disease diagnosis that enable clinicians to prevent and treat their patients with targeted interventions and precise drug dosing.
How does Precision Quantomics support non-animal testing initiatives?
The FDA’s recent roadmap to reduce reliance on animal testing has accelerated the demand for New Approach Methodologies (NAMs)—including microphysiological systems (MPS), organ-on-a-chip technologies, and advanced in vitro models. Precision Quantomics supports this transition by delivering quantitative proteomics assays specifically designed to characterize and qualify NAM platforms.